<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766140</url>
  </required_header>
  <id_info>
    <org_study_id>HR-FMTN-II/III-NSCLC-COM</org_study_id>
    <nct_id>NCT02766140</nct_id>
  </id_info>
  <brief_title>SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer</brief_title>
  <official_title>Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral SHR1020 Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Local Advanced or Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer After Failure of First Line Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel&#xD;
      in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more&#xD;
      effective as compared to placebo in combination with docetaxel. A secondary aim is to obtain&#xD;
      safety information as well as information on quality of life of patients treated with SHR1020&#xD;
      in combination with docetaxel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty in recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>approximately 30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>approximately 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Intensity of Adverse Events</measure>
    <time_frame>From signing informed consent document until 30 days after the last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumour Response (Complete Response Plus Partial Response) Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</measure>
    <time_frame>approximately 30months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control (Complete Response Plus Partial Response plus stable disease) Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</measure>
    <time_frame>approximately 30months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) measured by standardised questionnaires (EORTC Quality of Life Questionnaire-C30)</measure>
    <time_frame>approximately 30months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Non Squamous Non Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>SHR1020 plus Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Docetaxel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1020 plus Docetaxel</intervention_name>
    <description>SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m^2 IV Day1/3weeks</description>
    <arm_group_label>SHR1020 plus Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus Docetaxel</intervention_name>
    <description>Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m^2 IV Day1/3weeks</description>
    <arm_group_label>Placebo plus Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age:18-70 years&#xD;
&#xD;
          2. Histologically or cytologically confirmed locally advanced and/or metastatic NSCLC or&#xD;
             recurrent NSCLC (≤9 months from date of diagnosis to randomized ), epidermal growth&#xD;
             factor receptor-wild type, Anaplastic Lymphoma Kinase-wild type or unknown mutation&#xD;
&#xD;
          3. At least one lesion that can be accurately measured and has not been received local&#xD;
             treatments such as radiotherapy and cryotherapy&#xD;
&#xD;
          4. Relapse or failure of one first line prior platinum-based chemotherapy&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance status 0 or 1&#xD;
&#xD;
          6. Life expectancy of at least 12 weeks&#xD;
&#xD;
          7. Adequate organ and bone marrow function as defined below(no blood transfusion or drugs&#xD;
             for leucopenia and Platelet within 14 days before screening): (1) HB≥90g/l (2)&#xD;
             ANC≥1.5×10^9/l (3) PLT≥100×10^9/l (4) BIL&lt;1.25×upper limit of normal (5) Alanine&#xD;
             Aminotransferase and/or AST&lt;2.5×upper limit of normal (&lt; 5×upper limit of normal for&#xD;
             patients with liver metastasis) (6) Cr≤1.25×upper limit of normal or Creatinine&#xD;
             clearance rate&gt;45ml/min ( Cockcroft-Gault Formula) (7) Cholesterol≤1.5×upper limit of&#xD;
             normal, Triglyceride≤2.5×upper limit of normal (8) Left ventricular ejection fraction&#xD;
             (LVEF) greater than lower limit of normal&#xD;
&#xD;
          8. Female: child bearing potential, a negative urine or serum pregnancy test result&#xD;
             within 7 days before randomisation, agree to use effective contraception while on&#xD;
             treatment and for at least 6 months after end of treatment;male: agree to use&#xD;
             effective contraception while on treatment and for at least 6 months after end of&#xD;
             treatment&#xD;
&#xD;
          9. Patient has given written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than one prior chemotherapy regimen for advanced and/or metastatic or recurrent&#xD;
             NSCLC (except neoadjuvant or adjuvant chemotherapy )&#xD;
&#xD;
          2. Previous therapy with other VEGFR inhibitors、recombinant human endostatin、 docetaxel&#xD;
             or immunotherapy for treatment of NSCLC&#xD;
&#xD;
          3. History of severe hypersensitivity reactions to docetaxel or other drugs formulated&#xD;
             with polysorbate 80 (Tween 80), Hypersensitivity to the excipients of the trial drugs&#xD;
             or contrast medium&#xD;
&#xD;
          4. Have clinically significant cavity effusion,such as pleural effusion、 pericardial&#xD;
             effusion or ascites and require clinical intervention&#xD;
&#xD;
          5. Active brain metastases&#xD;
&#xD;
          6. Other malignancy within the past (including primary brain tumor or Leptomeningeal&#xD;
             tumor), other than basal cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          7. Significant weight loss (&gt;10%) within the past 6 weeks&#xD;
&#xD;
          8. Persistence of clinically relevant therapy related toxicities from previous therapy&#xD;
             (greater than Common Terminology Criteria for Adverse Event(CTCAE) 4.0 grade 1)&#xD;
&#xD;
          9. Treatment with surgery, chemotherapy, hormone therapy, radiotherapy, immunomodulation&#xD;
             or monoclonal antibody therapy within the past 4 weeks and traditional chinese&#xD;
             medicine for antitumor therapy within the past 2 weeks before start of therapy&#xD;
&#xD;
         10. Radiographical evidence of cavitary or necrotic tumours&#xD;
&#xD;
         11. Centrally located tumours with radiographical evidence (CT or MRI) of local invasion&#xD;
             of major blood vessels&#xD;
&#xD;
         12. Greater than CTCAE 4.0 grade 2 pulmonary hemorrhage within the past one month before&#xD;
             screening&#xD;
&#xD;
         13. History of clinically significant haemoptysis within the past 3 months (more than half&#xD;
             a teaspoon within 24 hours )&#xD;
&#xD;
         14. History of major thrombotic or clinically relevant major bleeding event in the past 6&#xD;
             months&#xD;
&#xD;
         15. Prothrombin time (PT) and/or partial thromboplastin time (PTT) &gt; 50% of devi&#xD;
&#xD;
               -  ation of upper limit of normal&#xD;
&#xD;
         16. Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or&#xD;
             its analogus, if INR≤1.5, with the purpose of prevention,the use of low-dose warfarin&#xD;
             (1mg, qd) or aspirin ( ≤ 100 mg per day ) is allowed&#xD;
&#xD;
         17. Incomplete wound healing or fracture for long time&#xD;
&#xD;
         18. Uncontrolled hypertensin with one antihypertensive agent, unstable angina, history of&#xD;
             myocardial infarction in the past 6 months, congestive heart failure&gt;NYHA II, serious&#xD;
             cardiac arrhythmia&#xD;
&#xD;
         19. Urinary protein≥++ and confirmed 24-hour urinary protein greater than 1.0g;&#xD;
&#xD;
         20. Preexisting thyroid dysfunction, even with medical therapy, thyroid function can not&#xD;
             be maintained in the normal range&#xD;
&#xD;
         21. Uncontrolled diabetes mellitus with antidiabetic therapy&#xD;
&#xD;
         22. Current peripheral neuropathy greater than CTCAE 4.0 grade 2&#xD;
&#xD;
         23. Active or chronic hepatitis C and/or B infection with liver dysfunction&#xD;
&#xD;
         24. History of immunodeficiency diseases, other acquired or congenital immunodeficiency&#xD;
             diseases, or history of organ transplantation&#xD;
&#xD;
         25. Serious infections requiring systemic antibiotic therapy&#xD;
&#xD;
         26. Variety of factors that affect the oral medication (such as unable to swallow, chronic&#xD;
             diarrhea, bowel obstruction and other gastrointestinal disorders or abnormalities&#xD;
&#xD;
         27. Pregnancy or breast feeding&#xD;
&#xD;
         28. Active alcohol or drug abuse&#xD;
&#xD;
         29. Treatment in another clinical trial within the past 4 weeks before start of therapy&#xD;
&#xD;
         30. Psychological, familial, sociological, or geographical factors potentially hampering&#xD;
             compliance with the study protocol and follow-up schedule&#xD;
&#xD;
         31. According to the investigator, other conditions that may increase the risk associated&#xD;
             with patient safety and study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>caicun zhou, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

